news10 May 2021Da Volterra is attending ChinaBio® Partnering Forum on May 12-14, 2021ChinaBio® Partnering Forum is the largest and most productive life science partnering event in China. During the digital portion of…more
news03 May 2021Da Volterra attending MEET2WIN European Oncology Partnering Convention on May 6-7, 2021MEET2WIN offers conferences addressing topical issues in oncology with internationally renowned speakers. The European Oncology Partnering Convention is entirely dedicated…more
news20 April 2021Florence Séjourné speaker at the JPIAMR Therapeutics workshop on April 20, 2021 at 13:30 CETAs AMR is an increasingly serious threat to global public health and threatens the effective prevention and treatment of infections,…more
news06 April 2021Da Volterra Receives FDA Fast Track Designation for its Novel Microbiome Protector DAV132 • FDA Fast Track Designation has been granted to DAV132 for the prevention of Clostridioides difficile infection, a life-threatening…more
news15 March 2021Da Volterra attending BIO-Europe Spring® Digital on March 22-25, 2021The “must-attend” BIO-Europe event series has gone digital, and continues to grow, proving its importance and relevance to the life…more
news08 March 2021New review published in Drug Discovery Today highlights the crucial role of the intestinal microbiome in health and disease and the need for microbiome protectorsDa Volterra is pleased to present the latest publication of the team on the role of the gut microbiome and…more
news03 February 2021Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate its Phase 3 Clinical Trial Evaluating the Microbiome Protector DAV132 in Patients with Hematologic Malignancies • World-first phase 3 study of a microbiome protector • Da Volterra becomes a pioneering late-stage clinical company…more
news18 December 2020Da Volterra’s CEO, Florence Séjourné, and CBO, Pierre-Alain Bandinelli, are attending Biotech Showcase™ Digital on January 11-15, 2021!Since its inception in 2009, Biotech Showcase has grown into one of the biopharma industry’s leading investor conferences, and is…more
news09 December 2020New data: confirmation of the negative impact of antibiotics on immuno-oncology patients’ survival in several types of cancersDa Volterra is presenting new data at the European Society for Medical Oncology (ESMO) Immuno-Oncology 2020 Virtual Meeting this week…more
news10 November 2020Da Volterra is presenting new data at Society for Immunotherapy of Cancer’s 2020 Virtual MeetingConfirmation of the negative impact of antibiotics on immuno-oncology patients’ survival Da Volterra is presenting new data at the Society…more
